Type 1 Diabetes Australian Research Impact Analysis

Type 1 Diabetes Australian Research Impact Analysis

Executive Overview Summary Type 1 diabetes research in Australia Australia is making a significant contribution to the quantity and quality of the global scientific literature in type 1 diabetes. Its growing presence in shaping the body of knowledge that is improving the lives of people with type 1 diabetes is internationally recognised and held in high esteem by the research community. Australia s contribution to the volume of global scientific literature in type 1 diabetes has almost doubled between 2003 and 2012 from 2.4 to 4.4% Australia ranks in the top ten countries in the quality of type 1 diabetes research published in the world Australia has the 6th largest proportion of type 1 diabetes publications focused on clinical research JDRF funds 15% of type 1 diabetes publications in Australia JDRF-funded publications in Australia are cited almost twice as many times as other publications

Introduction Type 1 Diabetes Research Impact Analysis Type 1 diabetes is a lifelong autoimmune disease that destroys the body s ability to produce insulin. Six new cases of type 1 diabetes are diagnosed in Australia every day. Only through advancements in medical research is there a hope for better treatments and a cure for this lifelong disease. Measuring the impact of research can be achieved by evaluating the volume and quality of scientific literature published in Australia. By analysing the impact of over 22,000 publications in type 1 diabetes publications between 2008 and 2012, the Type 1 Diabetes Global Research Impact Analysis identified leading and emerging contributors who are shaping the global landscape of type 1 diabetes research. Australia s role in advancing the scientific literature in type 1 diabetes was apparent its contribution to the global volume of literature almost doubled between 2003 and 2012. More importantly, these publications were of a superior quality and regarded in high esteem by the research community. Australia is growing as the global epicentre for breakthrough medical research in type 1 diabetes. The Type 1 Diabetes Research Impact Analysis helps increase our understanding of current and emerging leaders in the field. I am delighted to see the exceptional quality of Australian research and the increasing impact of our researchers on the global research landscape. Professor Warwick Anderson, Chief Executive Officer, National Health and Medical Research Council The Type 1 Diabetes Global Research Impact Analysis was conducted as a part of the Global Diabetes Research Innovation Partnership between the Macquarie Group Foundation and JDRF Australia.

Performance measures Performance measures Australia s contribution to the volume of global scientific literature has almost doubled between 2003 and 2012 Between 2008 and 2012, Australia produced 884 publications relevant to type 1 diabetes. Australia s share of the volume of global scientific literature in type 1 diabetes grew from 2.4 to 4.4% between 2003 and 2012, almost doubling within this period. The total number of publications was also nearly two-thirds higher in 2012 with 220 publications compared to 136 publications in 2008 (Figure 1). Figure 1 Australia has shown a 60% increase in the number of type 1 diabetes publications between 2008 and 2012 Number of type 1 diabetes publications 220 195 170 145 120 2008 2009 2010 2011 2012 Australia has the sixth largest proportion of type 1 diabetes publications focused on clinical research 39% of all publications in Australia were focused on clinical research, compared to a world average of 29% (Figure 2). Australia is a major global player in translating therapies from the laboratory to the clinic. Figure 2 Australia ranks in the top ten countries in the volume of published clinical research Percentage of clinical research publications (%) 60% 50% 40% 30% 20% 10% 0% Finland Norway Poland Hungary Russia Australia Denmark Singapore Sweden Netherlands Italy UK EU Israel Germany USA Spain Canada France Belgium World average

Australia ranks in the top ten countries in the quality of type 1 diabetes research published in the world The quality of publications can be measured by the number of times a publication is cited by other researchers, the esteem with which other researchers hold a publication and the quality of the peer-reviewed journal that the research was published in. These measures are defined by the number of citations, relative citation impact and relative journal impact, respectively. Australian publications rank in the top ten countries relative to the world average in these measures. A high proportion of Australian publications are in the top 10% of cited publications (Figure 3). Figure 3 Australia ranks in the top ten countries in the quality of type 1 diabetes publications in the world Relative journal impact 1.75 1.50 Finland 1.25 1.00 0.75 Japan World EU Spain Canada Norway France USA Sweden Italy UK Israel Germany Netherlands Switzerland Belgium Denmark Australia China 0.50 Poland 0.25 0.25 0.50 0.75 1.00 1.25 1.50 1.75 Relative citation impact Impact is measured by how well the publication is cited by the research community (relative citation impact) and the quality of the journal where the research was published (relative journal impact). This analysis was commissioned by JDRF to Prof. Linda Butler, an independent expert in the field of bibliometrics. Details about the methodology used in this analysis can be obtained by contacting JDRF.

JDRF s contribution JDRF s contribution JDRF funds 15% of type 1 diabetes publications in Australia Over 8% of type 1 diabetes publications in the world acknowledged JDRF as a funder. The distribution of publications arising due to JDRF funding varies between countries that have a physical JDRF presence. In Australia, 15% of the type 1 diabetes publications acknowledged JDRF as a funder. JDRF-funded publications in Australia are cited almost twice as many times as other publications Strikingly, almost double the proportion of JDRF-funded publications were in the top 10% of highly cited publications across the research discipline globally compared to publications not funded by JDRF. This shows that JDRF-funded publications are highly recognised by researchers across the world and are making a strong mark in developing the global understanding of type 1 diabetes (Figure 4). Figure 4 Australian type 1 diabetes publications are published in the top-tier of cited articles Proportion of publications in the top 10% of all global research publications JDRF-funded publications Non JDRF-funded publications 30% 25% 20% 15% 10% 5% 0% Australia Canada China Denmark Israel Netherlands UK USA EU World About JDRF JDRF is the leading not-for-profit supporter of type 1 diabetes research globally, investing over $1.7 billion in the world s best diabetes research since 1970 with over $100 million invested in Australia. Our support has been behind nearly every major advance in type 1 diabetes research in the last 40 years, resulting in increased quality of life and strong progress towards a cure. Through guiding the scientific agenda, accelerating the pace of research, and engaging with our key stakeholders like government agencies, we can deliver research progress directly to people with type 1 diabetes. The international structure of JDRF, with links to governments, research institutes and regulatory agencies, allows us to increase the value of the research dollar, provide a tangible return on investment and deliver real results that transform the lives of people with type 1 diabetes.